Navigate Complexities With HIV Therapy
August 2026
Doravirine/islatravir (Idvynso) is a new antiretroviral therapy (ART) that will raise questions about how to treat HIV.
It’s a single-tablet combo nucleoside reverse transcriptase inhibitor (NRTI) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Doravirine/islatravir is only for patients on a stable ART regimen who are virologically suppressed...haven’t failed previous ART...and have no known doravirine resistance.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote